

Application No. 09/580,018
Amendment After Allowance dated February 27, 2004
Response to the Notice of Allowance mailed December 3, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of prophylactically or therapeutically treating Alzheimer's disease comprising administering to the patient an effective dosage of a pharmaceutical composition comprising a human, humanized, or chimeric antibody that specifically binds to an epitope within A β 1-7, and thereby prophylactically or therapeutically treating the patient.

2-5. (Cancelled)

6. (Original) The method claim 1, wherein the antibody is of human isotype IgG1.

7. (Previously Presented) The method of any one of the preceding claims, wherein the patient is human.

8. (Original) The method of claim 1, wherein the antibody specifically binds to an epitope within residues 1-6 of A β .

9-10. (Cancelled)

11. (Original) The method of claim 1, wherein the antibody specifically binds to an epitope within residues 3-7 of A β .

12. (Original) The method of claim 1, wherein the antibody specifically binds to an epitope within residues 1-3 of A β .

13. (Original) The method claim 1, wherein the antibody specifically binds to an epitope within residues 1-4 of A β .

Application No. 09/580,018
Amendment After Allowance dated February 27, 2004
Response to the Notice of Allowance mailed December 3, 2003

14. (Original) The method of claim 1, wherein after administration the antibody binds to an amyloid deposit in the patient and induces a clearing response against the amyloid deposit.

15. (Original) The method of claim 14, wherein the clearing response is an Fc receptor mediated phagocytosis response.

16. (Original) The method of claim 15, further comprising monitoring the clearing response.

17-18. (Cancelled)

19. (Original) The method of claim 1, wherein the patient is asymptomatic.

20. (Original) The method of claim 1, wherein the patient is under 50.

21. (Original) The method of claim 1, wherein the patient has inherited risk factors indicating susceptibility to Alzheimer's disease.

22. (Original) The method of claim 1, wherein the patient has no known risk factors for Alzheimer's disease.

23. (Original) The method of claim 1, wherein the antibody is a human antibody.

24. (Original) The method of claim 1, wherein the antibody is a humanized antibody.

25. (Original) The method of claim 1, wherein the antibody is a chimeric antibody.

26. (Cancelled)

Application No. 09/580,018
Amendment After Allowance dated February 27, 2004
Response to the Notice of Allowance mailed December 3, 2003

27. (Original) The method of claim 1, wherein the antibody is a polyclonal antibody.
28. (Original) The method of claim 1, wherein the antibody is a monoclonal antibody.
29. (Original) The method of claim 1, further comprising administering an effective dosage of at least one other antibody that binds to a different epitope of A β .
30. (Original) The method of claim 1, wherein the isotype of the antibody is IgG1 or IgG4.
31. (Original) The method of claim 1, wherein the isotype of the antibody is IgG2 or IgG3.
32. (Original) The method of claim 1, wherein the antibody comprises two copies of the same pair of light and heavy chains.
- 33-34. (Cancelled)
35. (Original) The method of claim 1, wherein the dosage of antibody is at least 1 mg/kg body weight of the patient.
36. (Original) The method of claim 1, wherein the dosage of antibody is at least 10 mg/kg body weight of the patient.
37. (Previously Presented) The method of claim 1, wherein the antibody is administered with a carrier.
- 38-39. (Canceled)
40. (Original) The method of claim 1, wherein the antibody specifically binds to A β peptide without binding to full-length amyloid precursor protein (APP).

Application No. 09/580,018
Amendment After Allowance dated February 27, 2004
Response to the Notice of Allowance mailed December 3, 2003

41. (Previously Presented) The method of claim 1, wherein the antibody is administered intraperitoneally, orally, subcutaneously, intranasally, intramuscularly, topically, or intravenously.

42-43: (Cancelled)

44. (Original) The method of claim 1, further comprising monitoring the patient for level of administered antibody in the blood of the patient.

45-68. (Cancelled)

69. (Previously Presented) The method of claim 1, wherein the method further comprises monitoring a response to the administration of the antibody in the patient.

70. (Previously Presented) The method of claim 1, wherein a single dosage of the antibody is administered on multiple occasions.

71. (Previously Presented) The method of claim 70, wherein the single dosage is administered once every week, once per every two weeks, once a month, once every 3 to 6 months, or yearly.

72-75. (Cancelled)

76. (Previously Presented) The method of claim 70 or 71 wherein the occasions occur over a period of at least six months.